Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00042211
Status:
COMPLETED
Last Update Posted:
2014-01-08
First Post:
2002-07-24
Brief Title:
Preventing Depression in Patients With Macular Degeneration
Sponsor:
Thomas Jefferson University
Organization:
Thomas Jefferson University
Study Overview
Official Title:
Preventing Depression in Macular Degeneration
Status:
COMPLETED
Status Verified Date:
2008-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the effectiveness of a Problem Solving Treatment in preventing depression in elderly patients with age-related macular degeneration AMD
Detailed Description:
AMD is the most common cause of blindness in older adults The disease limits the ability to read see familiar faces and walk independently Almost 2 million persons about 5 percent of the US population over age 65 are now affected and this number will triple by the year 2020 This study will target patients with neovascular AMD NV-AMD a form of AMD which can lead to sudden vision loss substantial disability and depression Because depression is itself disabling and not likely to be recognized nor treated by ophthalmologists preventing depression in people with NV-AMD is important
Patients are randomly assigned to either PST or a usual care control condition The primary outcome measure is a DSM-IV diagnosis of depression Patients are evaluated at baseline Month 2 immediately post-intervention Month 6 for the primary efficacy analysis and Month 12 to evaluate sustained effects The study will also assess the impact of PST on levels of disability and vision-related quality of life
Patients are randomly assigned to either PST or a usual care control condition The primary outcome measure is a DSM-IV diagnosis of depression Patients are evaluated at baseline Month 2 immediately post-intervention Month 6 for the primary efficacy analysis and Month 12 to evaluate sustained effects The study will also assess the impact of PST on levels of disability and vision-related quality of life
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DATR A4-GPS | US NIH GrantContract | None | httpsreporternihgovquickSearchR01MH061331 |
| R01MH061331 | NIH | None | None |